Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation
Open Access

Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial

Kibrom B. Girum, Anne-Ségolène Cottereau, Laetitia Vercellino, Louis Rebaud, Jérôme Clerc, Olivier Casasnovas, Franck Morschhauser, Catherine Thieblemont and Irène Buvat
Journal of Nuclear Medicine February 2024, 65 (2) 313-319; DOI: https://doi.org/10.2967/jnumed.123.266322
Kibrom B. Girum
1LITO Laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne-Ségolène Cottereau
2Department of Nuclear Medicine, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laetitia Vercellino
3Department of Nuclear Medicine, Saint Louis Hospital, AP-HP, Paris, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Rebaud
1LITO Laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, France;
4Research and Clinical Collaborations, Siemens Medical Solutions USA, Knoxville, Tennessee;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jérôme Clerc
2Department of Nuclear Medicine, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Casasnovas
5Department of Hematology, University Hospital of Dijon, Dijon, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franck Morschhauser
6Research Group on Injectable Forms and Associated Technologies, Department of Hematology, Claude Huriez Hospital, University Lille, Lille, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Thieblemont
7Department of Hematology, Saint Louis Hospital, AP-HP, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irène Buvat
1LITO Laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 65 no. 2 313-319
DOI 
https://doi.org/10.2967/jnumed.123.266322
PubMed 
38071535

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication July 12, 2023
  • Revision received October 23, 2023
  • Published online February 1, 2024.

Article Versions

  • previous version (December 7, 2023 - 07:13).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2024 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

  1. Kibrom B. Girum1,
  2. Anne-Ségolène Cottereau2,
  3. Laetitia Vercellino3,
  4. Louis Rebaud1,4,
  5. Jérôme Clerc2,
  6. Olivier Casasnovas5,
  7. Franck Morschhauser6,
  8. Catherine Thieblemont7 and
  9. Irène Buvat1
  1. 1LITO Laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, France;
  2. 2Department of Nuclear Medicine, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France;
  3. 3Department of Nuclear Medicine, Saint Louis Hospital, AP-HP, Paris, France;
  4. 4Research and Clinical Collaborations, Siemens Medical Solutions USA, Knoxville, Tennessee;
  5. 5Department of Hematology, University Hospital of Dijon, Dijon, France;
  6. 6Research Group on Injectable Forms and Associated Technologies, Department of Hematology, Claude Huriez Hospital, University Lille, Lille, France; and
  7. 7Department of Hematology, Saint Louis Hospital, AP-HP, Paris, France
  1. For correspondence or reprints, contact Irène Buvat (irene.buvat{at}curie.fr).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 6 Citations
  • 6 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Organomics
    Yazdan Salimi, Ghasem Hajianfar, Zahra Mansouri, Amirhosein Sanaat, Mehdi Amini, Isaac Shiri, Habib Zaidi
    Clinical Nuclear Medicine 2024 49 10
  • Enhancing Lymphoma Diagnosis, Treatment, and Follow-Up Using 18F-FDG PET/CT Imaging: Contribution of Artificial Intelligence and Radiomics Analysis
    Setareh Hasanabadi, Seyed Mahmud Reza Aghamiri, Ahmad Ali Abin, Hamid Abdollahi, Hossein Arabi, Habib Zaidi
    Cancers 2024 16 20
  • Deep Learning–Powered CT-Less Multitracer Organ Segmentation From PET Images
    Yazdan Salimi, Zahra Mansouri, Isaac Shiri, Ismini Mainta, Habib Zaidi
    Clinical Nuclear Medicine 2025 50 4
  • Automatic Quantification of Serial PET/CT Images for Pediatric Hodgkin Lymphoma Using a Longitudinally Aware Segmentation Network
    Xin Tie, Muheon Shin, Changhee Lee, Scott B. Perlman, Zachary Huemann, Amy J. Weisman, Sharon M. Castellino, Kara M. Kelly, Kathleen M. McCarten, Adina L. Alazraki, Junjie Hu, Steve Y. Cho, Tyler J. Bradshaw
    Radiology: Artificial Intelligence 2025 7 3
  • Long-Axial Field-of-View PET Imaging in Patients with Lymphoma
    Clemens Mingels, Hande Nalbant, Hasan Sari, Felipe Godinez, Fatma Sen, Benjamin Spencer, Naseem S. Esteghamat, Joseph M. Tuscano, Lorenzo Nardo
    PET Clinics 2024 19 4
  • A Systematic Review of the Applications of Deep Learning for the Interpretation of Positron Emission Tomography Images of Patients with Lymphoma
    Theofilos Kanavos, Effrosyni Birbas, Theodoros P. Zanos
    Cancers 2024 17 1

Article usage

Article usage: December 2023 to April 2025

AbstractFullPdf
Dec 2023983746254
Jan 202421129182
Feb 2024413399105
Mar 202411926486
Apr 20247622372
May 20247212939
Jun 20244914455
Jul 20243625244
Aug 20243024347
Sep 2024337751
Oct 2024167445
Nov 2024339249
Dec 20242310752
Jan 2025318536
Feb 20252014431
Mar 2025218438
Apr 2025186536
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 65 (2)
Journal of Nuclear Medicine
Vol. 65, Issue 2
February 1, 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial
Kibrom B. Girum, Anne-Ségolène Cottereau, Laetitia Vercellino, Louis Rebaud, Jérôme Clerc, Olivier Casasnovas, Franck Morschhauser, Catherine Thieblemont, Irène Buvat
Journal of Nuclear Medicine Feb 2024, 65 (2) 313-319; DOI: 10.2967/jnumed.123.266322

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial
Kibrom B. Girum, Anne-Ségolène Cottereau, Laetitia Vercellino, Louis Rebaud, Jérôme Clerc, Olivier Casasnovas, Franck Morschhauser, Catherine Thieblemont, Irène Buvat
Journal of Nuclear Medicine Feb 2024, 65 (2) 313-319; DOI: 10.2967/jnumed.123.266322
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • [18F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis–Associated Interstitial Lung Disease
  • Whole-Body [18F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View
  • Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience
Show more Clinical Investigation

Similar Articles

Keywords

  • tumor location
  • FDG
  • CT
  • DLBCL
  • artificial intelligence
SNMMI

© 2025 SNMMI

Powered by HighWire